Dr. Reddy's Laboratories Limited
DRREDDY.NS
₹1170.20
▼ 1.00%
Dr. Reddy's Laboratories slipped 1% to ₹1170.20 after the US FDA flagged four observations following a GMP inspection at its FTO-3 formulations facility in Hyderabad conducted between August 6 and 14, 2026 — a smaller haul than the seven observations from a similar inspection back in June. The stock, now down nearly 17% from its 52-week high of ₹1414.9, has been a serial underperformer, shedding 7.34% over the past year and 8.33% over two years, even as its five- and ten-year returns of 4.92% and 6.72% suggest longer-term holders have fared somewhat better. Regulatory scrutiny has been a recurring theme for the company, with earlier disclosures made to exchanges in October 2023 and September 2025 as well. Of the 39 analysts covering the stock, the average price target sits at ₹1265.77, though there's currently no clear consensus call on the name.
CAGR Performance
| 1 Year | 2 Years | 5 Years | 10 Years |
|---|---|---|---|
| -6.49% | -8.27% | 5.06% | 6.79% |
Analyst Consensus
Average Target Price: ₹1265.77 (range ₹1039.00 - ₹1740.00) based on 39 analysts
Strong Buy: 4
Buy: 11
Hold: 11
Sell: 5
Strong Sell: 8
No comments:
Post a Comment